{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:15:37Z","timestamp":1778595337993,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","award":["161924"],"award-info":[{"award-number":["161924"]}],"id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Mycology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.mycmed.2022.101256","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T02:17:58Z","timestamp":1645150678000},"page":"101256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-089X","authenticated-orcid":false,"given":"M.","family":"Ehrensberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.W.C.","family":"Boal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Makarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Callanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mycmed.2022.101256_bib0001","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2018.03.062","article-title":"Onychomycosis: Clinical overview and diagnosis","volume":"80","author":"Lipner","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.mycmed.2022.101256_bib0002","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2133.1997.tb03673.x","article-title":"A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study","volume":"136","author":"Gupta","year":"1997","journal-title":"Br J Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.mycmed.2022.101256_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.mycmed.2022.101256_bib0004","first-page":"E21","article-title":"Onychomycosis: current and investigational therapies","volume":"94","author":"Lipner","year":"2014","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.mycmed.2022.101256_bib0005","first-page":"E16","article-title":"Over-the-counter and natural remedies for onychomycosis: do they really work?","volume":"98","author":"Halteh","year":"2016","journal-title":"Cutis"},{"issue":"10","key":"10.1016\/j.mycmed.2022.101256_bib0006","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archderm.142.10.1279","article-title":"Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients","volume":"142","author":"Szepietowski","year":"2006","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.mycmed.2022.101256_bib0007","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/jof4030087","article-title":"Challenges and opportunities in the management of onychomycosis","volume":"4","author":"Christenson","year":"2018","journal-title":"J Fungi"},{"issue":"6","key":"10.1016\/j.mycmed.2022.101256_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004105","article-title":"Fungal nail infections (onychomycosis): a never-ending story?","volume":"10","author":"Ghannoum","year":"2014","journal-title":"PLoS Pathogens"},{"issue":"7","key":"10.1016\/j.mycmed.2022.101256_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159661","article-title":"Efficacy coefficients determined using nail permeability and antifungal activity in keratin-containing media are useful for predicting clinical efficacies of topical drugs for onychomycosis","volume":"11","author":"Matsuda","year":"2016","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.mycmed.2022.101256_bib0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dks129","article-title":"Use of hydrogen peroxide as a biocide: new consideration of its mechanisms of biocidal action","volume":"67","author":"Linley","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.mycmed.2022.101256_bib0011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/0378-6323.95444","article-title":"Nail avulsion: indications and methods (surgical nail avulsion)","volume":"78","author":"Pandhi","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"10.1016\/j.mycmed.2022.101256_bib0012","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nature Methods"},{"key":"10.1016\/j.mycmed.2022.101256_bib0013","series-title":"Guideline for good clinical practice E6(R2)","year":"2016"},{"issue":"Suppl 1","key":"10.1016\/j.mycmed.2022.101256_bib0014","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2230.1992.tb00277.x","article-title":"Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly","volume":"17","author":"Lauharanta","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.mycmed.2022.101256_bib0015","unstructured":"clinicaltrial.gov. [cited 2019 08.01.2019]; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01851590?term=amorolfine&draw=2&rank=2]."},{"issue":"2","key":"10.1016\/j.mycmed.2022.101256_bib0016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2229-3485.71856","article-title":"Sample size estimation in clinical trial","volume":"1","author":"Sakpal","year":"2010","journal-title":"Perspect Clin Res"},{"issue":"4","key":"10.1016\/j.mycmed.2022.101256_bib0017","first-page":"225","article-title":"The uphill path to successful clinical trials: keeping patients enrolled","volume":"38","author":"Alexander","year":"2013","journal-title":"P t"},{"issue":"2","key":"10.1016\/j.mycmed.2022.101256_bib0018","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ijd.13690","article-title":"Examining the importance of laboratory and diagnostic testing when treating and diagnosing onychomycosis","volume":"57","author":"Ghannoum","year":"2018","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.mycmed.2022.101256_bib0019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.mycmed.2022.101256_bib0020","first-page":"407","article-title":"The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents","volume":"64","author":"Mehregan","year":"1999","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.mycmed.2022.101256_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.12594","article-title":"A second look at efficacy criteria for onychomycosis: clinical and mycological cure","volume":"170","author":"Ghannoum","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mycmed.2022.101256_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/09546630500504713","article-title":"Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison","volume":"17","author":"Sigurgeirsson","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.mycmed.2022.101256_bib0023","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1468-3083.2008.03036.x","article-title":"The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis","volume":"23","author":"Gupta","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.mycmed.2022.101256_bib0024","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1128\/AAC.38.7.1480","article-title":"Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase","volume":"38","author":"Kurtz","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mycmed.2022.101256_bib0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jaad.2006.12.019","article-title":"Onychomycosis: diagnosis and definition of cure","volume":"56","author":"Scher","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.mycmed.2022.101256_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/950358","article-title":"Hydroxypropyl-\u03b2-cyclodextrin: a novel transungual permeation enhancer for development of topical drug delivery system for onychomycosis","author":"Chouhan","year":"2014","journal-title":"J Drug Deliv"},{"issue":"2","key":"10.1016\/j.mycmed.2022.101256_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229414","article-title":"Assessment of the nail penetration of antifungal agents, with different physico-chemical properties","volume":"15","author":"Davies-Strickleton","year":"2020","journal-title":"PloS one"},{"issue":"5","key":"10.1016\/j.mycmed.2022.101256_bib0028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nhtm.2017.01.002","article-title":"Drug delivery through nails: present and future","volume":"3","author":"Shanbhag","year":"2017","journal-title":"Eur J Mol Clin Med"},{"issue":"1-2","key":"10.1016\/j.mycmed.2022.101256_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.10.002","article-title":"Transungual drug delivery: current status","volume":"384","author":"Elkeeb","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.mycmed.2022.101256_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejpb.2016.03.008","article-title":"An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates","volume":"102","author":"McAuley","year":"2016","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Journal of Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523322000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523322000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:19:14Z","timestamp":1778591954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523322000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1156523322000130"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2022.101256","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails","name":"articletitle","label":"Article Title"},{"value":"Journal of Medical Mycology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2022.101256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS on behalf of SFMM.","name":"copyright","label":"Copyright"}],"article-number":"101256"}}